Study of Minnelide™ in Patients With Advanced GI Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

December 31, 2016

Conditions
Advanced Gastrointestinal Tumors
Interventions
DRUG

Minnelide™ 001

Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.

Trial Locations (2)

55455

University of Minnesota Masonic Cancer Clinic, Minneapolis

85258

Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale

Sponsors
All Listed Sponsors
lead

Minneamrita Therapeutics LLC

INDUSTRY

NCT01927965 - Study of Minnelide™ in Patients With Advanced GI Tumors | Biotech Hunter | Biotech Hunter